ReviewPediatric investigation2025
Pediatric human immunodeficiency virus infection in the modern era: A systematic review of recent advances and their implications.
Review in Pediatric investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pediatric human immunodeficiency virus infection in the modern era: A systematic review of recent advances and their implications.Pediatric investigation · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Importance: Pediatric human immunodeficiency virus (HIV) infection continues to pose a significant global health burden, especially in low- and middle-income countries. Despite advances in antiretroviral therapy (ART), children living with HIV face unique clinical, developmental, and systemic challenges. Objective: To systematically review recent developments in pediatric HIV care, with a focus on treatment innovations, complications, and the transition from pediatric to adult care. Methods: A comprehensive literature review was conducted across PubMed, Scopus, EMBASE, and the World Health Organization databases, covering studies published between 2012 and 2025. Inclusion criteria focused on original research, clinical trials, and guidelines addressing pediatric ART, long-acting therapies, prevention strategies, treatment complications, and transitional care. Results: Early ART initiation was associated with improved neurodevelopment and reduced disease progression. Current pediatric ART regimens favor simplified combinations and weight-based dosing, but pharmacokinetic variability, toxicity, and adherence remain concerns. Long-acting injectable therapies, such as cabotegravir/rilpivirine and investigational agents like lenacapavir and islatravir, show promise for adolescents. Prevention of mother-to-child transmission has significantly reduced pediatric HIV incidence, largely through maternal ART and pre-exposure prophylaxis. However, stigma, poor awareness, and healthcare disparities hinder broader impact. Children on lifelong ART face increased risks of metabolic, cardiovascular, renal, and neurocognitive complications. Transitioning to adult care remains a vulnerable period with high rates of treatment disengagement. Interpretation: Advances in pediatric HIV care are substantial but uneven. Continued investment in age-appropriate therapies, psychosocial support, and implementation research is essential to close persistent gaps and ensure equitable, lifelong care for children and adolescents living with HIV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.